Here's what we'll cover
Here's what we'll cover
Can Ozempic or Wegovy Affect Your Vision?
Most people starting semaglutide expect nausea or constipation. Fewer expect questions about their eyes. Yet over the past two years, vision has become one of the most closely watched safety topics for GLP-1 medications, driven by research on a rare optic nerve condition called NAION and by a growing number of lawsuits.
Here is what the evidence actually shows, what regulators in the US and Europe have said, and what symptoms should send you to an eye doctor right away.
The Two Eye Issues Linked to GLP-1 Medications
When people talk about vision and GLP-1 drugs, they are usually talking about one of two separate problems.
1. Diabetic Retinopathy Complications
This one is already on the US label. In the SUSTAIN 6 trial of injectable semaglutide in people with type 2 diabetes, retinopathy complications were more common with semaglutide than with placebo. Researchers believe the main driver is a rapid drop in blood sugar, which can temporarily worsen existing diabetic eye disease. The Wegovy prescribing information advises monitoring patients with a history of diabetic retinopathy.
2. Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
NAION happens when blood flow to the front of the optic nerve drops suddenly, damaging the nerve. According to the American Academy of Ophthalmology, it typically causes painless vision loss in one eye, often noticed on waking, and the lost vision usually does not fully return. It is the condition behind most of the recent headlines.
What the Research Shows About NAION
The concern started with a 2024 study from Mass Eye and Ear published in JAMA Ophthalmology. Researchers reviewed records of patients seen at a neuro ophthalmology service and found higher NAION rates among those prescribed semaglutide:
| Group in the 2024 study | 36 month cumulative NAION incidence |
|---|---|
| Type 2 diabetes, semaglutide | 8.9% |
| Type 2 diabetes, other diabetes drugs | 1.8% |
| Overweight or obesity, semaglutide | 6.7% |
| Overweight or obesity, other weight loss drugs | 0.8% |
Those numbers came from a specialized referral population, so they are much higher than what the general public would experience. Larger studies since then have generally found a smaller signal. A 2025 analysis of tens of millions of people with type 2 diabetes reported only a modest increase in risk, and an April 2026 study of about 588,000 US veterans found 39.07 NAION cases per 10,000 GLP-1 users over three years compared with 29.33 per 10,000 among SGLT2 inhibitor users, as summarized by Medical Daily.
None of these observational studies proves that semaglutide causes NAION. Diabetes, high blood pressure, and sleep apnea all raise NAION risk on their own, and those conditions are common in people who take GLP-1 medications.
What Regulators Have Said
In June 2025, the European Medicines Agency's safety committee concluded that NAION is a very rare side effect of semaglutide medicines, meaning it may affect up to 1 in 10,000 people. European product information for Ozempic, Rybelsus, and Wegovy was updated accordingly. The World Health Organization issued a statement the same month noting the finding.
In the United States, the FDA added NAION and GLP-1 receptor agonists to its quarterly list of potential safety signals in 2025 and said it was evaluating the need for regulatory action. As of September 2026, US labels for Ozempic, Wegovy, Rybelsus, and Mounjaro still did not list NAION, according to Medical Daily. A signal on that list does not mean the FDA has concluded the drugs cause the problem.
The Lawsuits
Vision loss claims have been consolidated in federal court in Philadelphia. As of September 1, 2026, 216 cases were part of the multidistrict litigation, and the judge ordered that general causation and federal preemption be addressed first, with briefing scheduled for 2027. Litigation outcomes are not medical evidence, but they are one reason the issue keeps appearing in the news.
How Big Is the Risk for You?
Put in perspective, NAION is rare. The EMA frequency estimate of up to 1 in 10,000 is far smaller than the risk of common side effects like nausea, which affect a large share of users. At the same time, NAION can permanently reduce vision, so it is worth taking seriously, especially if you already have risk factors.
You may be at higher baseline risk if you have:
- A crowded optic disc, sometimes called a disc at risk, which an eye doctor can see on exam
- Untreated or poorly controlled obstructive sleep apnea
- High blood pressure, especially with low blood pressure overnight
- Type 2 diabetes or significant cardiovascular disease
- A previous episode of NAION in either eye
Symptoms That Need Prompt Attention
Contact an eye doctor or go to urgent care the same day if you notice:
- Sudden, painless loss or dimming of vision in one eye
- A dark area or shadow in the upper or lower half of your vision
- Colors looking washed out in one eye compared with the other
- Blurred vision that does not clear with blinking or rest
Mild, fluctuating blurriness early in treatment can also happen as blood sugar levels shift. It still deserves a call to your prescriber, but it is different from sudden vision loss.
Practical Steps Before and During Treatment
- Get a baseline dilated eye exam if you have diabetes, a history of eye disease, or sleep apnea.
- Tell your prescriber about any prior optic nerve or retinal problems.
- Treat sleep apnea and keep blood pressure controlled, since both affect optic nerve blood flow.
- If you have diabetic retinopathy, ask whether a slower dose escalation makes sense to avoid a sudden drop in blood sugar.
- Do not stop your medication on your own because of headlines. Talk with your doctor about your personal risk and benefits.
Questions to Ask Your Doctor
- Do I have any risk factors for NAION, such as a crowded optic disc or untreated sleep apnea?
- Should I see an ophthalmologist before starting or increasing my dose?
- How will we monitor my eyes if I have diabetic retinopathy?
- Would a different GLP-1 or a slower titration lower my risk?
- What exactly should I do if I notice sudden vision changes?
No waiting list. No insurance needed.
Frequently Asked Questions
Can Ozempic or Wegovy cause blindness?
Semaglutide has been associated with NAION, a rare optic nerve condition that can cause permanent vision loss in one eye. European regulators classify it as a very rare side effect affecting up to 1 in 10,000 people. Total blindness is not typical, and causation has not been proven in US labeling.
What is NAION?
Nonarteritic anterior ischemic optic neuropathy is a sudden loss of blood flow to the front of the optic nerve. It usually causes painless vision loss in one eye, often noticed on waking, and the lost vision frequently does not fully return.
Has the FDA added a NAION warning to Ozempic or Wegovy?
The FDA listed NAION as a potential safety signal for GLP-1 receptor agonists in 2025 and said it was evaluating regulatory action. As of September 2026, US labels for Ozempic, Wegovy, Rybelsus, and Mounjaro did not include NAION, while European labels list it as a very rare side effect.
Does semaglutide make diabetic retinopathy worse?
It can. In the SUSTAIN 6 trial, diabetic retinopathy complications were more common with semaglutide than placebo, likely because blood sugar fell quickly. People with existing retinopathy should be monitored by an eye doctor during treatment.
Who is most at risk for NAION on GLP-1 drugs?
People with a crowded optic disc, untreated sleep apnea, high blood pressure, type 2 diabetes, cardiovascular disease, or a prior NAION episode have higher baseline risk. Discuss these factors with your doctor before starting treatment.
What should I do if my vision changes on semaglutide?
Seek same day care from an eye doctor or urgent care for sudden, painless vision loss in one eye, a dark shadow in part of your vision, or washed out colors. Call your prescriber about milder blurriness, and do not stop your medication without guidance.
The Bottom Line
Semaglutide has a clear, labeled association with worsening diabetic retinopathy when blood sugar drops quickly, and a rarer, still debated association with NAION. European regulators classify NAION as a very rare side effect affecting up to 1 in 10,000 people. The FDA has flagged the signal but had not added it to US labels as of September 2026.
For most people, the cardiometabolic benefits of Wegovy or Ozempic outweigh this small risk, but that calculation depends on your eyes, your sleep, and your blood pressure. Get a baseline eye exam if you are at higher risk, know the warning signs, and act fast if your vision changes suddenly.
If you want a prescriber who will screen for these risks before you start, compare vetted telehealth providers. Always consult your physician before starting, stopping, or changing any GLP-1 medication.